Johnson & Johnson (NYSE:JNJ) Trading Up 3.1% – What’s Next?

Johnson & Johnson (NYSE:JNJ) shares traded up 3.1% on Tuesday . The company traded as high as $269.43 and last traded at $267.3470. 8,980,344 shares were traded during mid-day trading, an increase of 6% from the average session volume of 8,459,440 shares. The stock had previously closed at $259.33.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Investors appear encouraged by Johnson & Johnson’s raised 2026 outlook and solid first-quarter results, which showed stronger sales and reinforced expectations for another good quarter ahead of July 15 earnings. Johnson & Johnson (JNJ) Unveils New IMAAVY Data With Broader Reach In View
• Positive Sentiment: Wall Street has been raising price targets, with recent calls pointing to stronger drug sales and steady demand across J&J’s pharma and medtech businesses, which is helping support the stock near record highs. Johnson & Johnson Gains as Higher Outlook and Pre-Earnings Optimism Support Shares
• Positive Sentiment: Recent product and pipeline momentum, including progress in oncology, immunology and medtech, is adding to the bullish case for Johnson & Johnson as investors look for durable growth drivers. Johnson & Johnson Likely To Report Higher Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
• Neutral Sentiment: Large, unusual put option activity suggests some traders are hedging or betting on a pullback after the recent run-up, but this is more of a cautionary signal than a clear fundamental warning. Unusual Put Option Activity in Johnson & Johnson After JNJ Stock’s Recent Runup
• Negative Sentiment: Some of J&J’s recent insider sales and mixed institutional positioning may temper enthusiasm, though they do not outweigh the stronger earnings and outlook narrative driving the stock today. Johnson & Johnson Gains as Higher Outlook and Pre-Earnings Optimism Support Shares

Analyst Upgrades and Downgrades

JNJ has been the subject of several analyst reports. Morgan Stanley set a $283.00 price target on shares of Johnson & Johnson in a research report on Wednesday, April 15th. Sanford C. Bernstein increased their price objective on shares of Johnson & Johnson from $225.00 to $251.00 and gave the company a “market perform” rating in a report on Wednesday, April 15th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $265.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, April 15th. Weiss Ratings lowered Johnson & Johnson from a “buy (b)” rating to a “buy (b-)” rating in a research note on Monday, June 15th. Finally, Wells Fargo & Company increased their price target on shares of Johnson & Johnson from $240.00 to $263.00 and gave the stock an “overweight” rating in a report on Wednesday, April 15th. Twenty investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $257.13.

Johnson & Johnson Trading Up 3.1%

The business’s fifty day moving average price is $233.72 and its 200 day moving average price is $231.37. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $643.56 billion, a PE ratio of 30.91, a P/E/G ratio of 2.58 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The firm had revenue of $24.06 billion for the quarter, compared to analyst estimates of $23.60 billion. During the same period in the previous year, the company posted $2.77 EPS. Johnson & Johnson’s revenue for the quarter was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, analysts expect that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were issued a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 2.0%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date was Tuesday, May 26th. Johnson & Johnson’s dividend payout ratio is 61.97%.

Insider Transactions at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the sale, the executive vice president owned 114,288 shares of the company’s stock, valued at $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.16% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Johnson & Johnson

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Blueline Advisors LLC bought a new position in Johnson & Johnson in the fourth quarter valued at about $25,000. Cresta Advisors Ltd. bought a new position in Johnson & Johnson in the 4th quarter worth about $26,000. DecisionPoint Financial LLC boosted its stake in shares of Johnson & Johnson by 104.2% in the 4th quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock valued at $30,000 after purchasing an additional 75 shares in the last quarter. Family CFO Inc bought a new stake in Johnson & Johnson in the fourth quarter valued at $31,000. Finally, Bay Harbor Wealth Management LLC grew its stake in Johnson & Johnson by 49.0% in the fourth quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock worth $31,000 after purchasing an additional 49 shares during the period. Institutional investors own 69.55% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.